Repository logo
 
Publication

Advanced Glycation End Products Evolution after Pancreas-Kidney Transplantation: Plasmatic and Cutaneous Assessments

dc.contributor.authorMartins, L.
dc.contributor.authorOliveira, J.
dc.contributor.authorVizcaíno, J.
dc.contributor.authorFonseca, R.
dc.contributor.authorGouveia, C.
dc.contributor.authorSilva, D.
dc.contributor.authorCastro-Henriques, A.
dc.contributor.authorNoronha, I.
dc.contributor.authorRodrigues, A.
dc.date.accessioned2017-07-11T11:01:17Z
dc.date.available2017-07-11T11:01:17Z
dc.date.issued2016
dc.description.abstractDiabetes mellitus leads to increased Advanced Glycation End Products (AGE) production, which has been associated with secondary diabetic complications. Type 1 diabetic patients undergoing pancreas-kidney transplantation (SPKT) can restore normoglycemia and renal function, eventually decreasing AGE accumulation. We aimed to prospectively study AGE evolution after SPKT. Circulating AGE were assessed in 20 patients, at time 0 (T0), 3 months (T3), 6 months (T6), and 12 months (T12) after successful SPKT. Global AGE and carboxymethyllysine (CML) were analyzed, as well as advanced oxidation protein products (AOPP). Skin biopsies were obtained at T0 and T12. Immunohistochemistry with anti-AGE antibody evaluated skin AGE deposition. AGE mean values were 16.8 ± 6.4 μg/mL at T0; 17.1 ± 3.8 μg/mL at T3; 17.5 ± 5.6 μg/mL at T6; and 16.0 ± 5.2 μg/mL at T12. CML mean values were 0.94 ± 0.36 ng/mL at T0; 1.11 ± 0.48 ng/mL at T3; 0.99 ± 0.42 ng/mL at T6; and 0.78 ± 0.38 ng/mL at T12. AOPP mean values were 130.1 ± 76.8 μMol/L at T0; 137.3 ± 110.6 μMol/L at T3; 116.4 ± 51.2 μMol/L at T6; and 106.4 ± 57.9 μMol/L at T12. CML variation was significant (P = 0.022); AOPP variation was nearly significant (P = 0.076). Skin biopsies evolved mostly from a cytoplasmic diffuse to a peripheral interkeratinocytic immunoreaction pattern; in 7 cases, a reduction in AGE immunoreaction intensity was evident at T12. In conclusion, glycoxidation markers decrease, plasmatic and on tissues, may start early after SPKT. Studies with prolonged follow-up may confirm these data.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationOxid Med Cell Longev. 2016;2016:2189582pt_PT
dc.identifier.doi10.1155/2016/2189582pt_PT
dc.identifier.issn1942-0900
dc.identifier.issn1942-0994
dc.identifier.urihttp://hdl.handle.net/10400.16/2147
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherHindawi Publishing Corporationpt_PT
dc.relation.publisherversionhttps://www.hindawi.com/journals/omcl/2016/2189582/pt_PT
dc.titleAdvanced Glycation End Products Evolution after Pancreas-Kidney Transplantation: Plasmatic and Cutaneous Assessmentspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceUnited States of Americapt_PT
oaire.citation.startPage2189582pt_PT
oaire.citation.titleOxidative Medicine and Cellular Longevitypt_PT
oaire.citation.volume2016pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Advanced Glycation End Products.pdf
Size:
3.36 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.35 KB
Format:
Item-specific license agreed upon to submission
Description: